Commercially available preparations of human α1AT, such as Prolastin used in this study as well as others, are obtained through purification of donated blood and have been approved for the treatment of patients with genetic α1AT deficiency for decades. This evidence concerns the gene SERPINA1 and hyperinsulinemic hypoglycemia, familial, 4.